A Phase 1 interventional study of KarXT and KarX-EC in Healthy Volunteers, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 1 site in United States. Open to participants aged 19 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses of KarXT + KarX-EC capsules versus KarXT capsules in healthy adult and elderly participants of Japanese ethnicity and to assess the effect of multiple doses of omeprazole on the exposure of xanomeline and trospium administered as KarXT + KarX-EC capsules in healthy adult participants.
Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy adult participants must be 19 to 55 years of age, inclusive.
i) Both participant's biological parents are of ethnic Japanese ancestry. Participants must be first generation Japanese.
ii) Must have a (BMI) of 18.0 to 32.0 kg/m2 (inclusive), at the time of signing the ICF.
iii) Must have an estimated (eGFR) of ≥ 90 mL/min/1.73m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at the screening visit. One repeat measurement is allowed.
Healthy elderly participants must be 56 to 90 years of age, inclusive.
i) Both participant's biological parents are of ethnic Japanese ancestry. Participants must be first generation Japanese.
ii) Must have a BMI ≥ 18.0 and ≤ 35.0 kg/m2 (inclusive), at the time of signing the ICF.
iii) Must have an eGFR of > 60 mL/min/1.73m2 by the CKD-EPI equation at the screening visit. One repeat measurement is allowed.
Healthy adult participants must be 19 to 55 years of age, inclusive.
i) Participants with any ethnicity can be included.
ii) Must have a BMI of 18.0 to 32.0 kg/m2 (inclusive), at the time of signing the ICF.
iii) Must have an eGFR of ≥ 90 mL/min/1.73m2 by the CKD-EPI equation at the screening visit. One repeat measurement is allowed.
Exclusion Criteria
- Exclusion Criteria for All Participants (Groups A, B, C, and D):.
i) Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
ii) History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee.
iii) Participant has a history of syncope and/or symptomatic orthostatic hypotension in the year prior to Day 1.
iv) History of cancer that has not been in full remission for >5 years (except basal cell skin cancer or squamous cell skin cancer with history of curative treatment and no recurrence for > 1 year prior to the screening visit).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KarXT · Drug: Placebo
Drug: KarXT · Drug: Placebo
Drug: KarXT · Drug: KarX-EC · Drug: Placebo
Drug: KarXT · Drug: KarX-EC · Drug: Omeprazole
Drug pages: Xanomeline · Trospium
Specified dose on specified days
Also known as: BMS-986510, Xanomeline/Trospium Chloride
Specified dose on specified days
Also known as: BMS-986519, Xanomeline Enteric-coated
Specified dose on specified days
Specified dose on specified days
Number of participants with Adverse Events (AEs)
Part 1
Time frame: Up to 28 days post last dose
Number of participants with Serioues AEs (SAEs)
Part 1
Time frame: Up to 28 days post last dose
Number of participants with vital sign abnormalities
Part 1
Time frame: Up to 28 days post last dose
Body weight
Part 1
Time frame: Up to 28 days post last dose
Number of participants with 12-lead electrocardiogram abnormalities
Part 1
Time frame: Up to 28 days post last dose
Number of participants with physical examination abnormalities
Part 1
Time frame: Up to 28 days post last dose
Number of participants with clinical laboratory assessment abnormalities
Part 1
Time frame: Up to 28 days post last dose
Columbia-Suicide Severity Rating Scale (C-SSRS)
Part 1
Time frame: On Day 30
Maximum observed plasma concentration (Cmax)
Part 2
Time frame: Up to Day 29
Time of maximum observed plasma concentration (Tmax)
Part 2
Time frame: Up to Day 29
Area under the concentration-time curve in 1 dosing interval (AUC(TAU))
Part 2
Time frame: Up to Day 29
Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24))
Part 2
Time frame: Up to Day 29
Apparent total body clearance (CLT/F)
Part 2
Time frame: Up to Day 29
Apparent volume of distribution (Vz/F)
Part 2
Time frame: Up to Day 29
Terminal elimination half-life (T-HALF)
Part 2
Time frame: Up to Day 29
Cmax
Part 1
Time frame: Up to Day 29
Tmax
Part 1
Time frame: Up to Day 29
AUC(0-24)
Part 1
Time frame: Up to Day 29
AUC(TAU)
Part 1
Time frame: Up to Day 29
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Part 1
Time frame: Up to Day 29
CLT/F
Part 1
Time frame: Up to Day 29
Vz/F
Part 1
Time frame: Up to Day 29
T-HALF
Part 1
Time frame: Up to Day 29
Number of participants with AEs
Part 2
Time frame: Up to 28 days post last dose
Number of participants with SAEs
Part 2
Time frame: Up to 28 days post last dose
Number of participants with vital sign abnormalities
Part 2
Time frame: Up to 28 days post last dose
Body weight
Part 2
Time frame: Up to 28 days post last dose
Number of participants with 12-lead electrocardiogram abnormalities
Part 2
Time frame: Up to 28 days post last dose
Number of participants with physical examination abnormalities
Part 2
Time frame: Up to 28 days post last dose
Number of participants with clinical laboratory assessment abnormalities
Part 2
Time frame: Up to 28 days post last dose
C-SSRS
Part 2
Time frame: On Day 30
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Oct 2024 to primary completion in May 2025, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium · Omeprazole
Karuna Therapeutics, Inc., a Bristol Myers Squibb company →